Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21620367 | 0.91 | FFAR1 (0.65) | FFAR1HTR2CHTR2BMAPTKDM4E | |
| SCHEMBL2736379 | 0.86 | FFAR1 (0.49) | FFAR1HTR2CHTR2BCYP1A2CYP2C9 | |
| SCHEMBL13026533 | 0.84 | FFAR1 (0.43) | FFAR1HTR2CHTR2BMAPTHPGD | |
| SCHEMBL14997977 | 0.83 | HTR2A (0.50) | FFAR1HTR2CHTR2BMAPTKDM4E | |
| SCHEMBL22114334 | 0.81 | TTR (0.46) | FFAR1HTR2CHTR2BMAPTCYP2C9 | |
| SCHEMBL22069710 | 0.81 | PDE7A (0.54) | FFAR1HTR2CHTR2BMAPTKDM4E | |
| SCHEMBL8297380 | 0.81 | MAOA (0.60) | FFAR1HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL2171467 | 0.81 | FFAR1 (0.57) | FFAR1MAPTNPSR1PNLIP | |
| SCHEMBL2509239 | 0.80 | PDE7A (0.56) | FFAR1MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL3438989 | 0.79 | MAPT (0.62) | FFAR1MAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786492-B2 | Therapeutic agent for phosphodiesterase inhibition and its related disorders | NOVALEAD PHARMA INC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220000813-A1 | Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders | NOVALEAD PHARMA INC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11147779-B2 | Therapeutic agent for phosphodiesterase inhibition and its related disorders | Deshpande, Supreet K. (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147779-B2 | Therapeutic agent for phosphodiesterase inhibition and its related disorders | PDE9A, PDE3A, PDE12 | FFAR1 484/4885HTR2C 1045/4885HTR2B 535/4885 |
| US-11786492-B2 | Therapeutic agent for phosphodiesterase inhibition and its related disorders | PDE3A, PDE9A, PDE12 | FFAR1 518/4885HTR2C 1044/4885HTR2B 559/4885 |
| US-20220000813-A1 | Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders | PDE3A, PDE9A, PDE12 | FFAR1 518/4885HTR2C 1044/4885HTR2B 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.